Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B NFOyU4hCeG:ydH;zbZMhSXO|YYm= M{T1[FHjiJN3wrFOwG0> NFzsPGE1QCCq NX7Qd|ZFcW6qaXLpeJMh[2WubDDndo94fGh? M2nGTlI3OzJ7NkC4
PLC/PRF/5  MmnKRZBweHSxc3nzJGF{e2G7 NXv2Um1IOeLCk{ZCpO69VQ>? M1;3PVQ5KGh? MX7pcohq[mm2czDj[YxtKGe{b4f0bC=> MWGyOlMzQTZyOB?=
HepG2  MVfBdI9xfG:|aYOgRZN{[Xl? MX6x5qCUPcLizszN MmnzOFghcA>? MkDtbY5pcWKrdIOgZ4VtdCCpcn;3eIg> Mnn6NlY{Ojl4MEi=
HEK293 NGi0c5VHfW6ldHnvckBCe3OjeR?= NVjPOpllOC534pEJ{txO MXSyM|QwPiCq MlXwdoVlfWOnczDHVnA4QCCneIDy[ZN{cW:w M{jXeFI2QDV6MEOy
GEO NWW1WXFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vLSFAvODFvMkCg{txO MVe5OkBp M4HpNWROW09? MVLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MW[yOVg{QDN7MR?=
SW48 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:5NE4xOS1{MDFOwG0> NIf4SIk6PiCq NV\0VIszTE2VTx?= NYS2WIJscW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlHpNlU5Ozh|OUG=
HT29 NUXnN2R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XUblAvODFvMkCg{txO MWS5OkBp NF7yNIFFVVOR NVXnfoxkcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF7DTGgzPTh|OEO5NS=>
SW480 M{TTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTXTpAxNjBzLUKwJO69VQ>? NFLEW5c6PiCq MVvEUXNQ NVzpXZpNcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3\hXlI2QDN6M{mx
SW620 NIj1[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW5cJc4OC5yMT2yNEDPxE1? NE\LeIo6PiCq MV\EUXNQ NYS5R3c2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXqyOVg{QDN7MR?=
HCT116 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWwMlAyNTJyIN88US=> MmryPVYhcA>? NVy1UG9iTE2VTx?= NH\JZZJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmjONlU5Ozh|OUG=
LOVO NIjIfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DOUlAvODFvMkCg{txO M3mwelk3KGh? Mn\ISG1UVw>? M4HBPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVXub|BOOjV6M{izPVE>
HCT150 NUDUNmlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjMNld5OC5yMT2yNEDPxE1? MWW5OkBp M{DD[mROW09? NWjVSlVjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX6yOVg{QDN7MR?=
SW48-CR NY[4XlFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXhO2kxNjBzLUKwJO69VQ>? NXHrdVFLQTZiaB?= MnrWSG1UVw>? NGfQ[ndqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1jEelI2QDN6M{mx
GEO-CR NHj3[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XDeVAvODFvMkCg{txO NVzvSYJtQTZiaB?= NUHZdFNPTE2VTx?= M1vOO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3LwSFI2QDN6M{mx
KB-31 M{HO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3PZ4lKSzVyPUWuOeKyOC5|IH7N MoDkNlU4PTN|NkG=
KB-G2 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\0eXpxUUN3ME25MlHDuTBwMTDuUS=> M3\YbFI2PzV|M{[x
LLC-PK1 M4njeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPiTWM2OD12Mj6wxtE{NjJibl2= M2C4WFI2PzV|M{[x
LLC-PK1/MRP2 NESzc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrvOJV7UUN3ME24Nk41yrF{Lkegcm0> NFntW|YzPTd3M{O2NS=>
HEK293 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSxO5ZVUUN3ME2xNU4xyrFzLkKgcm0> NXXHV4ExOjV5NUOzOlE>
HEK293/OATP1B1 NEG0NJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTZwMtMxNE4{KG6P NEDyc4ozPTd3M{O2NS=>
HROC18 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfu[mJKSzVyPUGuN{DPxE1? MV6yOVMxQTlzNB?=
HROC24 NGnIXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHx[YNHUUN3ME20MlYh|ryP MUiyOVMxQTlzNB?=
HROC43 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTVwMzFOwG0> NEPjbo0zPTNyOUmxOC=>
HROC46 NEG5cpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTQZ5J4UUN3ME2yMlQh|ryP MVGyOVMxQTlzNB?=
RJ345 MlHSSpVv[3Srb36gRZN{[Xl? MlqxNE42NzVizszN MViyOEBp NIW3T|ZFVVOR NWHGSpdWcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v MUSyOVI2Ozl7NB?=
RJ348 MUXGeY5kfGmxbjDBd5NigQ>? M{\ZblAvPS93IN88US=> MVuyOEBp NFfvRotFVVOR NXrOVFlocW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v MYGyOVI2Ozl7NB?=
MCF-7 M4rwb2Z2dmO2aX;uJGF{e2G7 Mn\ENE42NzVizszN MWGyOEBp NYrxW3Q2TE2VTx?= NGLpTW1qdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> M4\V[FI2OjV|OUm0
MDA-MB-231 Mn\2SpVv[3Srb36gRZN{[Xl? MWqwMlUwPSEQvF2= M1\hT|I1KGh? MXjEUXNQ NWm0[nlocW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v MkfONlUzPTN7OUS=
HT15 NIrrZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLCZZgyNTJyIN88US=> MmKxOFghcA>? MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoX6NlUxPzFyMUi=
DLD1 MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fheFEuOjBizszN MmfDOFghcA>? NGjEbmZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXTLRWpOOjVyN{GwNVg>
HT-29 M3;XcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHKTJRtOS1{MDFOwG0> MY[0PEBp MlOzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVSyOVA4OTBzOB?=
Hct-116 NHy3SnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr0bpZEOS1{MDFOwG0> NVPEbpMyPDhiaB?= MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHO5VI4zPTB5MUCxPC=>
HT15 M4jwZ2Fxd3C2b4Ppd{BCe3OjeR?= NVrEdJB6OS1zMDFOwG0> MXy0PEBp NWHTOYE4cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUCyOVA4OTBzOB?=
DLD1 M2XLemFxd3C2b4Ppd{BCe3OjeR?= MYSxMVExKM7:TR?= NFfVd3A1QCCq MmTPbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M37NXlI2ODdzMEG4
HT-29 NIDZ[W5CeG:ydH;zbZMhSXO|YYm= NVPT[VhDOS1zMDFOwG0> M1LGXVQ5KGh? NXzhTFVCcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlWxNlUxPzFyMUi=
Hct-116 NI\OSZhCeG:ydH;zbZMhSXO|YYm= NGL3SWIyNTFyIN88US=> NWnjTpFCPDhiaB?= MnvvbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1foOlI2ODdzMEG4
GBM5 MUjBdI9xfG:|aYOgRZN{[Xl? NFvHe24xNjYkgKOxMlDjiIoQvF2= NV;vVXNPOjRiaB?= MXLEUXNQ M{i0OIlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> NYDHd|RYOjR7MUGyNVU>
GBM6 MYDBdI9xfG:|aYOgRZN{[Xl? MYSwMlXjiJNzLkFihKnPxE1? NIGz[|EzPCCq NIe4bWdFVVOR MmrZbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo MVuyOFkyOTJzNR?=
GBM12 MmXxRZBweHSxc3nzJGF{e2G7 NIDKeYoxNjYkgKOxMlDjiIoQvF2= M{LKelI1KGh? MYHEUXNQ NGD0OpRqdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> M3jrO|I1QTFzMkG1
GBM14  MUTBdI9xfG:|aYOgRZN{[Xl? NVvCXWpjOC534pETNU4x6oDLzszN M1rNUlI1KGh? NIr4foJFVVOR MnTPbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo NIDMNGkzPDlzMUKxOS=>
Hep3B NGfCRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jpOFHjiJN{LkZCpO69VQ>? MmjKNlQwPDhxN{KgbC=> M{LGTolvcGmkaYTzJINmdGxiZ4Lve5Rp MYeyOFg5PTh7MB?=
PLC/PRF/5  MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLsSYpROeLCk{KuOeKh|ryP M4PaclI1NzR6L{eyJIg> NVra[pVXcW6qaXLpeJMh[2WubDDndo94fGh? NG\KO2szPDh6NUi5NC=>
HepG2  M120Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPRNgKBmzJwNdMg{txO MVqyOE81QC95MjDo M4fWO4lvcGmkaYTzJINmdGxiZ4Lve5Rp NYTmVWpHOjR6OEW4PVA>
HCT116  NIXkOpJHfW6ldHnvckBCe3OjeR?= NYHyenlMOTBxMkCvOFAh|ryP Mn\zNlQhcA>? MmXIbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdiCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NWLxcZZEOjR5NkO2NVE>
Lim2405 NXPzNIFDTnWwY4Tpc44hSXO|YYm= MlLDOFAh|ryP NIHvVWgzPCCq NXHNeJpEcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MYSyOFc3OzZzMR?=
LoVo M{HzV2Z2dmO2aX;uJGF{e2G7 NYnEbXQxPDBizszN NX73[2VyOjRiaB?= M3niZ4lv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NIL3bmUzPDd4M{[xNS=>
Lim1215 MYXGeY5kfGmxbjDBd5NigQ>? MUK0NEDPxE1? MWSyOEBp Mme2bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MXyyOFc3OzZzMR?=
SW48 NF3pSJpHfW6ldHnvckBCe3OjeR?= MYK0NEDPxE1? M{nVU|I1KGh? NGDVSopqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NGjtR4YzPDd4M{[xNS=>
RKO  NGDKd5RHfW6ldHnvckBCe3OjeR?= MYG0NEDPxE1? MUGyOEBp MVrpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MknrNlQ4PjN4MUG=
SW837 MVPGeY5kfGmxbjDBd5NigQ>? MUC0NEDPxE1? NInU[WUzPCCq M2\KUIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? MYiyOFc3OzZzMR?=
SW1463 MkPSSpVv[3Srb36gRZN{[Xl? NFLVNY01OCEQvF2= MWqyOEBp M3;2cYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M2fZc|I1PzZ|NkGx
SW480 NHv6OmFHfW6ldHnvckBCe3OjeR?= MnGxOFAh|ryP MV:yOEBp MoXVbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NEWyU3QzPDd4M{[xNS=>
Vaco432 MYDGeY5kfGmxbjDBd5NigQ>? MW[0NEDPxE1? MUGyOEBp M33EZYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M2nuV|I1PzZ|NkGx
Vaco400 MVXGeY5kfGmxbjDBd5NigQ>? NGn3VIw1OCEQvF2= M1fiSVI1KGh? MXjpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> M3TOXFI1PzZ|NkGx
DLD1 M{X2bmZ2dmO2aX;uJGF{e2G7 NX\kU5dmPDBizszN M1HNWlI1KGh? NYfKcZp7cW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NYTrbFQ6OjR5NkO2NVE>
HT29  Ml3YSpVv[3Srb36gRZN{[Xl? MVG0NEDPxE1? M17tclI1KGh? MoXYbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NX;GWZRVOjR5NkO2NVE>
PLC/PRF/5  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVex5qCUPcL3TR?= NUPmXmhmOjRxNEivO|IhcA>? MnT2bY5pcWKrdIOgZ4VtdCCpcn;3eIg> NV31bmxKOjNzNkmxOFg>
HepG2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXMe|ky6oDVNdM1US=> MV6yOE81QC95MjDo Mn3sbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NX;yN3c4OjNzNkmxOFg>
Hep3B  M2f1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHp[|Ay6oDVNdM1US=> Mor2NlQwPDhxN{KgbC=> NVf3b4VxcW6qaXLpeJMh[2WubDDndo94fGh? Mo\MNlMyPjlzNEi=

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID